NASDAQ:EXAS

Exact Sciences - EXAS Stock Forecast, Price & News

$36.06

-0.10 (-0.28%)

(As of 10/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $34.81
▼
$36.06
50-Day Range: $31.97
▼
$49.37
52-Week Range: $31.62
▼
$104.50

Volume: 1.89 million shs
Average Volume: 2.17 million shs
Market Capitalization: $6.38 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $69.14

Exact Sciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 91.7% Upside
$69.14 Price Target
Short Interest: Bearish
6.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.66
Upright™ Environmental Score
News Sentiment: 0.76
Based on 6 Articles This Week
Insider Trading: Selling Shares
$208,005 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.22) to ($3.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

234th out of 1,072 stocks

Medical Laboratories Industry

8th out of 29 stocks

4.4

Analyst's Opinion

Consensus Rating
Exact Sciences has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.14, Exact Sciences has a forecasted upside of 91.7% from its current price of $36.06.
Amount of Analyst Coverage
Exact Sciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.34% of the outstanding shares of Exact Sciences have been sold short.
Short Interest Ratio / Days to Cover
Exact Sciences has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in Exact Sciences has recently increased by 14.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Exact Sciences does not currently pay a dividend.
Dividend Growth
Exact Sciences does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exact Sciences has received a 65.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private colorectal cancer diagnostics services" product. See details.
Environmental Sustainability
The Environmental Impact score for Exact Sciences is -0.66.

2.1

News and Social Media Coverage

News Sentiment
Exact Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Exact Sciences this week, compared to 2 articles on an average week.
Search Interest
Only 24 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,005.00 in company stock.
Percentage Held by Insiders
Only 1.30% of the stock of Exact Sciences is held by insiders.
Percentage Held by Institutions
90.95% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Exact Sciences are expected to grow in the coming year, from ($4.22) to ($3.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exact Sciences is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exact Sciences is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exact Sciences has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exact Sciences (NASDAQ:EXAS) Stock

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Stock News Headlines

October 3, 2022 | marketbeat.com

Is Illumina Still the Gamechanger in Genomics Sequencing? (EXAS)

Genome sequencing solutions company Illumina (NASDAQ: ILMN) stock has fallen under its pandemic lows. A surprise earnings miss, and lowered guidance has caused

October 3, 2022 | finance.yahoo.com

Would Exact Sciences Acquire Invitae? Unlikely.

September 30, 2022 | barrons.com

Premarket Movers: Nike Cl B, Exact Sciences, Olaplex

September 29, 2022 | finance.yahoo.com

YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?

September 29, 2022 | finance.yahoo.com

3 Growth Stocks That Could Double Your Money, According to Wall Street

September 28, 2022 | finance.yahoo.com

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

September 20, 2022 | seekingalpha.com

EXAS Exact Sciences Corporation

September 20, 2022 | finance.yahoo.com

Exact Sciences (EXAS) Cologuard Business Grows Amid Cost Woes

September 20, 2022 | finance.yahoo.com

Blood Tests for Cancer Look More Competitive. What It Means for Illumina’s Antitrust Fight.

September 13, 2022 | nasdaq.com

Interesting EXAS Put And Call Options For January 2025

September 8, 2022 | bizjournals.com

Madison cancer startup founded by former Exact Sciences exec raises $42M

September 8, 2022 | nasdaq.com

EXAS October 28th Options Begin Trading

September 1, 2022 | finance.yahoo.com

Exact Sciences (EXAS) Down 25.3% Since Last Earnings Report: Can It Rebound?

August 30, 2022 | finance.yahoo.com

Exact Sciences: Don't Deem It Guilty by Association

August 30, 2022 | finance.yahoo.com

Cathie Wood Goes Bargain-Shopping: 3 Stocks She Just Bought

August 25, 2022 | thestreet.com

Exact Sciences Corporation (EXAS) Falls Further As It's Water-Logged And Getting Wetter

August 25, 2022 | seekingalpha.com

Exact Sciences, Guardant rise as Credit Suisse initiates coverage with bullish views

August 25, 2022 | markets.businessinsider.com

What 9 Analyst Ratings Have To Say About Exact Sciences

August 24, 2022 | finance.yahoo.com

Here's Why You Should Retain Exact Sciences (EXAS) Now

August 23, 2022 | finance.yahoo.com

Ginkgo Bioworks is Toying With Wall Street

August 22, 2022 | nasdaq.com

Oversold Conditions For EXACT Sciences Corp. (EXAS)

August 15, 2022 | seekingalpha.com

Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely

August 3, 2022 | finance.yahoo.com

Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down

August 3, 2022 | finance.yahoo.com

Exact Sciences Stock Falls After Earnings. Here’s What Wall Street Is Saying.

August 3, 2022 | finance.yahoo.com

Exact Sciences (EXAS) Q2 2022 Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive EXAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.

EXAS Company Calendar

Last Earnings: 8/02/2022
Today: 10/06/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:EXAS
CUSIP: 30063P10
CIK: 1124140
Web: www.exactsciences.com
Phone: (608) 284-5700
Fax: 608-284-5701
Employees: 6,500
Year Founded: 1995

Price Target and Rating

Average Stock Price Forecast: $69.14
High Stock Price Forecast: $130.00
Low Stock Price Forecast: $40.00
Forecasted Upside/Downside: +91.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-595,630,000.00
Net Margins: -37.90%
Pretax Margin: -38.51%
Return on Equity: -22.07%
Return on Assets: -11.19%

Debt

Debt-to-Equity Ratio: 0.70
Current Ratio: 2.48
Quick Ratio: 2.23

Sales & Book Value

Annual Sales: $1.77 billion
Price / Sales: 3.61
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $19.66 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 176,960,000
Free Float: 174,660,000
Market Cap: $6.38 billion
Optionable: Optionable
Beta: 1.34

Social Links

Key Executives

Mr. Kevin T. Conroy (Age 56)
Chairman of The Board & CEO
Comp: $2.37M

Mr. Jeffrey T. Elliott CFA (Age 44)
Exec. VP, CFO & COO
Comp: $904.67k

Mr. D. Scott Coward (Age 57)
Chief Legal Officer
Comp: $847.28k

Mr. Graham P. Lidgard (Age 73)
Emeritus Chief Science Officer
Comp: $937.04k

Mr. Everett V. Cunningham (Age 56)
Chief Commercial Officer
Comp: $1.01M

Dr. Jorge A. Garces Ph.D. (Age 50)
Chief Science Officer

Mr. Sri Kalluri
Chief Information Officer

Ms. Megan Jones
Associate Mang. of Investor Relations

Mr. Tim Caprez
Chief Compliance Counsel & VP

Mr. Vic Parker
Head of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EXAS Stock - Frequently Asked Questions

Should I buy or sell Exact Sciences stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.
What is Exact Sciences' stock price forecast for 2022?: 12 analysts have issued 1 year price targets for Exact Sciences' stock. Their EXAS share price forecasts range from $40.00 to $130.00. On average, they anticipate the company's stock price to reach $69.14 in the next twelve months. This suggests a possible upside of 91.7% from the stock's current price.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.
How have EXAS shares performed in 2022?: Exact Sciences' stock was trading at $77.83 on January 1st, 2022. Since then, EXAS shares have decreased by 53.7% and is now trading at $36.06.
View the best growth stocks for 2022 here.
When is Exact Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our EXAS earnings forecast.
How were Exact Sciences' earnings last quarter?: Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings data on Tuesday, August, 2nd. The medical research company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.13. The medical research company had revenue of $521.64 million for the quarter, compared to the consensus estimate of $496.75 million. Exact Sciences had a negative net margin of 37.90% and a negative trailing twelve-month return on equity of 22.07%.
What guidance has Exact Sciences issued on next quarter's earnings?: Exact Sciences updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.98 billion-$2.02 billion, compared to the consensus revenue estimate of $2.02 billion.
What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?: 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

What other stocks do shareholders of Exact Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).
What is Exact Sciences' stock symbol?: Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."
Who are Exact Sciences' major shareholders?: Exact Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Curbstone Financial Management Corp (0.01%) and AdvisorNet Financial Inc (0.00%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Mark Stenhouse, Sarah Condella and Torsten Hoof.
View institutional ownership trends.
How do I buy shares of Exact Sciences?: Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Exact Sciences' stock price today?: One share of EXAS stock can currently be purchased for approximately $36.06.
How much money does Exact Sciences make?: Exact Sciences (NASDAQ:EXAS) has a market capitalization of $6.38 billion and generates $1.77 billion in revenue each year. The medical research company earns $-595,630,000.00 in net income (profit) each year or ($4.23) on an earnings per share basis.
How many employees does Exact Sciences have?: The company employs 6,500 workers across the globe.
Does Exact Sciences have any subsidiaries?: The following companies are subsidiares of Exact Sciences: Armune BioScience, Ashion Analytics, Base Genomics Limited, Biomatrica Inc., Exact Sciences Development Company LLC, Exact Sciences Laboratories LLC, Genomic Health Inc., Genomic Health International Holdings LLC, Paradigm Diagnostics Inc., Sampleminded Inc., Thrive Earlier Detection Corporation, and Viomics Inc..
Read More
How can I contact Exact Sciences?: Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.

This page (NASDAQ:EXAS) was last updated on 10/6/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Exact Sciences - EXAS Stock Forecast, Price & News

Exact Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Exact Sciences (NASDAQ:EXAS) Stock

EXAS Stock News Headlines

EXAS Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

EXAS Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™